orally-available drug for the treatment of cancer cachexia . Phase 2 clinical trials are expected to commence for both product candidates in early 2015 with projected completion dates in 2016. S-1 ETFs: IBB , BIB , BIS IPO Post your comment!
trial, it demonstrated clinically meaningful reductions in PSA (prostate specific antigen). IPO proceeds will fund a Phase 3 trial for galeterone that is expected to commence in 1H 2015. S-1 ETFs: IBB , BIB , BIS IPO Post your comment!
label into other indications, like preeclampsia (PE). Proceeds from IPO will fund the Phase 3 trial of Atryn to manage PE, ramp up the sales effort and for general corporate purposes. S-1 ETFs: IBB , BIB , BIS IPO Post your comment!
single protein is defective. Its lead product is the Orphan Drug-designated QR-010 for the treatment of Cystic Fibrosis (CF). It has only been evaluated in preclinical studies, however. F-1 ETFs: IBB , BIB , BIS IPO Post your comment!
labeling of a 71% success rate after eight days and 96% after 12 days. The company plans to initiate Phase 3 clinicals for FMX101 for acne in 2015 as well as FMX102 for impetigo in 2H 2015. F-1 ETFs: IBB , BIB , BIS IPO Post your comment!
Biotech IPOs set for next week: Foamix Pharaceuticals (FOMX); ProQR Therapeutics (PRQR); rEVO Biologics (RBIO); Tokai Pharmaceuticals (TKAI); Viking Therapeutics (VKTX) ETFs: IBB , BIB , BIS IPO Post your comment!
For news about this issuer, double click on the issuer RIC,
disease. Polypills potentially combine multiple drugs (e.g. aspirin, beta-blocker, statin, ACE-inhibitor) in one pill to treat cardiovascular disorders. ETFs: IBB , BIB , IRY , BIS , IXJ , DRGS Briefing docs Post your comment!
and sync information to the Qardio cloud. Qardio has generated substantial buzz over its portable monitoring technology. It also provides a wearable ECG monitor called QardioCore. ETFs: IBB , BIB , IRY , IXJ , BIS , DRGS Post your comment!
market-cap-weighted option is iShares Nasdaq Biotechnology IBB , which holds 121 Nasdaq-listed ..... market cap of $16.3 billion. IBB charges an expense ratio of 0 ..... holding cost of just 0.27%. IBB has a low price tag, historically